Skip to content
High Tech Early Stage Founded 1999

Minerva Biotechnologies

Minerva Biotechnologies develops cell therapy and antibodies to treat cancer, focusing on cancer immunotherapies that target solid tumors and prevent cancer metastasis. Founded in 1999 in Waltham, United States, the company has raised $18.9M in early stage funding from investors including HHS and Springboard Enterprises. Developer of cell therapy and antibodies to treat cancer. The company develops cancer…

📍 Waltham, United States · Nanotechnology,

Funding snapshot

Last roundEarly Stage
Amount$5M
Date14 November 2023
Total raised$19M
Team size17

About

Minerva Biotechnologies develops cell therapy and antibodies to treat cancer, focusing on cancer immunotherapies that target solid tumors and prevent cancer metastasis. Founded in 1999 in Waltham, United States, the company has raised $18.9M in early stage funding from investors including HHS and Springboard Enterprises. Developer of cell therapy and antibodies to treat cancer. The company develops cancer immunotherapies to target solid tumors and to prevent cancer metastasis. The company operates in the nanotechnology space. Founded in 1999, headquartered in Waltham, United States. The team comprises 17 (Jun 30, 2026) employees. Backed by investors including HHS, Springboard Enterprises. Minerva Biotechnologies is recognized as a minicorn..

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,

Oncology > Drugs > Breast Cancer

Team background

College Wise > Harvard University

Institutional investors

HHS Springboard Enterprises

Latest coverage

No articles yet.

Raising like Minerva Biotechnologies?

Analyze your pitch deck before your next raise.

Analyze My Deck →